semaglutide cardiovascular outcomes news today 2025 and in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial 🚨 Breaking News: Real-World Data

doi: 10.3390/ijms23020739 Summary Keywords metabolic reprogramming, glucagon-like peptide-1 receptor agonists, heart failure, cardiovascular system, diabetes Citation Wang X, Qi M, Yang L, Yang L, Wang X, Zhang F, Cui Y, Wang D, Wang Y and Lv W (2025) GLP-1 receptor agonists synergistic effects of metabolic reprogramming and cardioprotection

No phase III clinical trial in humans has been published to date in indexed journals

Your GP is the appropriate first point of contact and can assess your overall health, discuss evidence-based treatment options, and refer you to specialist services where appropriate

They are presented for educational purposes only

And how you do it matters

Our mission is to help you embrace these changes with confidence